Cyprotex
Cyprotex, a part of Evotec, specializes in ADME-Tox solutions, enabling and enhancing the prediction of human exposure, clinical efficacy, and toxicological outcomes of drugs or chemicals. They combine robust in vitro methods with contemporary in silico technology to add value, context, and relevance to ADME-Tox data for their partners in the pharmaceutical and chemical industries.
Industries
Nr. of Employees
medium (51-250)
Products
Cardiac electrophysiology assay using MEA and iPSC cardiomyocytes
High-throughput electrophysiology platform measuring whole-cell electrical activity and ECG-like responses in iPSC-derived cardiomyocytes for cardiotoxicity screening.
Neuronal electrophysiology assay using MEA
High-throughput MEA-based monitoring of primary cortical neurons to quantify spiking, bursting and network synchrony for neurotoxicity studies.
High-content multi-endpoint cell toxicology panel
Multiparametric high-content screening panels across multiple cell types and time points to assess diverse toxicological endpoints and support hepatotoxicity prediction when combined with exposure data.
3D microtissue and multilayer in vitro models
Three-dimensional and multilayered tissue constructs for more physiologically relevant toxicity and efficacy testing.
In silico PK/PD and exposure prediction tools
Computational workflows to predict human exposure metrics (e.g., Cmax) that are used alongside in vitro data for safety assessment.
Cardiac electrophysiology assay using MEA and iPSC cardiomyocytes
High-throughput electrophysiology platform measuring whole-cell electrical activity and ECG-like responses in iPSC-derived cardiomyocytes for cardiotoxicity screening.
Neuronal electrophysiology assay using MEA
High-throughput MEA-based monitoring of primary cortical neurons to quantify spiking, bursting and network synchrony for neurotoxicity studies.
High-content multi-endpoint cell toxicology panel
Multiparametric high-content screening panels across multiple cell types and time points to assess diverse toxicological endpoints and support hepatotoxicity prediction when combined with exposure data.
3D microtissue and multilayer in vitro models
Three-dimensional and multilayered tissue constructs for more physiologically relevant toxicity and efficacy testing.
In silico PK/PD and exposure prediction tools
Computational workflows to predict human exposure metrics (e.g., Cmax) that are used alongside in vitro data for safety assessment.
Services
Laboratory assays to generate ADME and PK parameters to inform exposure and drug disposition.
Cellular and tissue-based assays for mechanistic and predictive toxicology including cardiotoxicity, neurotoxicity and hepatotoxicity assessment.
Experimental measurement of solubility, lipophilicity and other physicochemical parameters to support formulation and ADME assessment.
Computational PK/PD and exposure modelling to predict human exposure metrics and support interpretation of in vitro findings.
Web-based ordering system for standardized ADME-Tox services.
Laboratory assays to generate ADME and PK parameters to inform exposure and drug disposition.
Cellular and tissue-based assays for mechanistic and predictive toxicology including cardiotoxicity, neurotoxicity and hepatotoxicity assessment.
Experimental measurement of solubility, lipophilicity and other physicochemical parameters to support formulation and ADME assessment.
Computational PK/PD and exposure modelling to predict human exposure metrics and support interpretation of in vitro findings.
Web-based ordering system for standardized ADME-Tox services.
Expertise Areas
- ADME / PK testing
- In vitro toxicology and DILI prediction
- Physicochemical property profiling
- PK/PD and exposure modelling
Key Technologies
- Multi-well microelectrode arrays (MEA)
- iPSC-derived cardiomyocytes
- Primary cortical neuron cultures
- High-content screening (HCS)